CN105770087A - Mongolian medicine composition for treating diabetes mellitus, hyperlipidemia and primary hyperviscosity - Google Patents
Mongolian medicine composition for treating diabetes mellitus, hyperlipidemia and primary hyperviscosity Download PDFInfo
- Publication number
- CN105770087A CN105770087A CN201610154734.4A CN201610154734A CN105770087A CN 105770087 A CN105770087 A CN 105770087A CN 201610154734 A CN201610154734 A CN 201610154734A CN 105770087 A CN105770087 A CN 105770087A
- Authority
- CN
- China
- Prior art keywords
- mongolian medicine
- medicine composition
- diabetes
- parts
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 59
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 39
- 239000000203 mixture Substances 0.000 title claims abstract description 34
- 208000031226 Hyperlipidaemia Diseases 0.000 title abstract description 3
- 239000008280 blood Substances 0.000 claims description 32
- 210000004369 blood Anatomy 0.000 claims description 32
- 201000005577 familial hyperlipidemia Diseases 0.000 claims description 11
- 239000002994 raw material Substances 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 12
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 2
- 241000132446 Inula Species 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 35
- 239000008103 glucose Substances 0.000 description 35
- 235000001727 glucose Nutrition 0.000 description 26
- 102000007330 LDL Lipoproteins Human genes 0.000 description 18
- 108010007622 LDL Lipoproteins Proteins 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 235000012054 meals Nutrition 0.000 description 10
- 206010056997 Impaired fasting glucose Diseases 0.000 description 8
- 238000003745 diagnosis Methods 0.000 description 8
- 201000009104 prediabetes syndrome Diseases 0.000 description 8
- 235000000346 sugar Nutrition 0.000 description 7
- 210000002700 urine Anatomy 0.000 description 7
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 230000003908 liver function Effects 0.000 description 6
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 5
- 206010020710 Hyperphagia Diseases 0.000 description 5
- 208000004880 Polyuria Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 206010036067 polydipsia Diseases 0.000 description 5
- 208000022530 polyphagia Diseases 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 5
- 208000002705 Glucose Intolerance Diseases 0.000 description 4
- 208000001280 Prediabetic State Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 206010025482 malaise Diseases 0.000 description 4
- 230000000291 postprandial effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 3
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 3
- 208000005946 Xerostomia Diseases 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 206010013781 dry mouth Diseases 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 230000011218 segmentation Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 229940116269 uric acid Drugs 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 208000008454 Hyperhidrosis Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 108060008539 Transglutaminase Proteins 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000037315 hyperhidrosis Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 239000010977 jade Substances 0.000 description 2
- 238000009533 lab test Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 102000003601 transglutaminase Human genes 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 238000002562 urinalysis Methods 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- -1 GOT 63 μ/L Proteins 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000016222 Pancreatic disease Diseases 0.000 description 1
- 108010076181 Proinsulin Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 235000009392 Vitis Nutrition 0.000 description 1
- 241000219095 Vitis Species 0.000 description 1
- 206010048245 Yellow skin Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000002804 anti-anaphylactic effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000002304 glucoses Chemical class 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 208000037921 secondary disease Diseases 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 235000021163 supper Nutrition 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 235000021147 sweet food Nutrition 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/346—Platycodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a Mongolian medicine composition for treating diabetes mellitus, hyperlipidemia and primary hyperviscosity. The Mongolian medicine composition comprises inula, fructus gardeniae, radix platycodonis, rhizoma coptidis and lignum sappan. The Mongolian medicine composition has the advantages that good curative effects can be realized by the Mongolian medicine composition; the obvious curative effects can be realized by the Mongolian medicine composition for corresponding symptoms, the Mongolian medicine composition can become effective fast and is free of toxic and side effects, and the like.
Description
Technical field
The present invention relates to mongolian medicine preparation field, especially, relate to a kind of mongolian medicine compositions treating diabetes, hyperlipemia, constitutional high blood viscosity.
Background technology
The understanding Huangdi's Internal Classics the earliest of diabetes is recorded xerostomia and polyuria by China, and symptom more than three is recorded by a section of quenching one's thirst for Han dynasty<twoth century of Christian era>Zhang Zhongjing " gold is deficient " completely.Western countries' diabetic history: B.C. 20 year 56 years Christian era AulusCornelius (Oulu this. Cornelius) be Europe first describe diabetic symptom people.1788 Cowley (examining profit) depict diabetes patient's pancreatic disorders, describe the Morphological Features of islets of langerhans.VonMerring (Feng. plum forests) and Minkowski (Minkowski) after within 1889, observing Canis familiaris L. excision pancreas, namely find diabetes.Nineteen twenty-one is found that animal Proinsulin, and in order to commemorate the inventor of insulin, the birthday of the winner Banting (the class court of a feudal ruler) of the Nobel Prize, it is " world's diabetes day " that World Health Organization (WHO) and International Diabetes Federation establish annual November 14.Research pancreas graft and artificial langerhans ' islet treat diabetes all over the world at present.The mongolian medicine record to diabetic symptom: mentioning uncommon clean sick, diabetes in " traditional Mongolian medicine ancient books is classical " Gan lu si bu, Lan Tabu (Mongolian) mentions the Ba Dagan that becomes thin, and has diabetes etc. in four doctor's allusion quotations.Within 1987, publish with " uncommon and that is uncommon clean " sick book " Chinese medicine encyclopaedical (traditional Mongolian medicine) " recorded the earliest." the Mongolian medicine's internal medicine teaching material " published for 1987 is recorded so that " uncommon and Xi Ge throws away " is sick.With " uncommon uncommon clean with you " sick record on " the Mongolian medicine's internal medicine teaching material " published for 2011.
Diabetes are frequently-occurring disease, commonly encountered diseases, and the worldwide public health problem of serious threat human health, sickness rate steeply rises.Our country's prevalence also quickly increases equally, and existing adult onset leads 9.7%, and the ratio of prediabetes is up to 15.5%, and more seriously 60% diabetics is not also diagnosed.Diagnosis does not obtain medical treatment for the some patients of diabetes, and accepts half patient blood glucose in treatment and control undesirable.Diabetes rejuvenation trend is obvious, 40-50 year " cause type " personage's sickness rate the fastest, diabetes mellitus in China patient 92,400,000 becomes diabetes the first big country.And people are inadequate to the understanding of diabetes, pay little attention to when prediabetes, early stage and cause the increasing the weight of of the state of an illness, merge multiple complications, ultimately result in the deformity of health.
Diabetes be by the various virulence factors such as inherited genetic factors, immunologic function disorder, microorganism infection and toxin, free radical toxin, Nervous and Mental Factors act on body cause hypoinsulinism, insulin resistant etc. and cause sugar, protein, fat, a series of metabolism disorder syndromes such as power and water Xie Zhi, clinically with hyperglycemia for main feature, abroad claiming it is " reticent killer ".According to statistics, the number of current China diabetics has reached 92,400,000.Within 2010, Chinese Adult diabetes prevalence male is 12.1%, and women is 11%；Urbanite's prevalence is 14.3%, and urban residents are 10.3%.Estimate according to International Diabetes Federation before, now the total diabetics more than 300,000,000 in the whole world.The new diabetes mellitus in China sickness rate data issued mean that the diabetes patient in the whole world 1/3rd is from China.And this numeral short 3 years China compared with 2007 has been increased by 22,000,000 diabetes patients, nearly equivalent to Australia's whole nation population summation.Professor Ning Guang represents, diabetes mellitus in China sickness rate belongs to one of the highest country in Asia, and absolute number is that the whole world is maximum.The ratio of prediabetes, up to 15.5%, is exactly specifically post-prandial glycemia (namely carbohydrate tolerance weakens) between 7.8 to 11.1, or fasting glucose state of (i.e. impaired fasting glucose (IFG)) between 6.1 to 7.0.And the diabetics of China about 2/3rds does not carry out enough glycemic control.This captures diabetes early, it is simply that the institute of its negative social responsibility becomes for numerous medical personal, just once described diabetes, and has systematic treating to describe, and also obtained good checking in long-term clinical practice in Mongolian medicine's Four-Volume Medical Code.In recent years we clinically apply illiteracy Western medicine combine treatment this disease achieve good curative effect.This disease carrying out so this time setting up the project the clinical observation research of system, giving full play to the advantage of Mongolia Medicine, developing the best prescription for the treatment of primary disease, the generation to improve improvement rate and prevention and minimizing complication is necessary.
Summary of the invention
It is an object of the present invention to provide the mongolian medicine compositions of a kind of eutherapeutic treatment diabetes, hyperlipemia, constitutional high blood viscosity.
Especially, described mongolian medicine compositions is made up of following weight proportion raw material: Radix Inulae: 1-2 part, Fructus Gardeniae: 3-6 part, Radix Platycodonis: 10-15 part, Rhizoma Coptidis: 5-10 part, Lignum Sappan: 5-8 part.
It is preferably: Radix Inulae: 1.5 parts, Fructus Gardeniae: 4.5 parts, Radix Platycodonis: 12 parts, Rhizoma Coptidis: 8 parts, Lignum Sappan: 6 parts.
Mongolian medicine compositions of the present invention can make the dosage form that any applicable patient takes by means commonly known in the art, such as powder, tablet, capsule etc..
Especially, it is contemplated that prepare and take convenient, powder can be prepared into, using method is a 2.5-3g, every day 3-4 time, warm boiled water.The course for the treatment of is 1-3 month.
Choosing side's foundation
1, draw half hot and oiliness is wished with bitterness for Zhu Yao town.
2, draw sharp is wished with shield for Zhu Yao town.
3, dry oiliness is reached with the medicine Zhenba without oils and fats effect.
4, dry sinking is reached based on medicine Zhenba gently.
5, clearing away heat from blood, please be muddy blood, trophema voxel.
The present invention, when Technical Design, has fully taken into account the synergism between each composition, and experienced by composition and the ratio optimization of three different phases, simultaneously, it is contemplated that some drugs composition would be likely to occur poison woman's effect, for instance Fructus Gardeniae side effect:
The ethanol extract large bolus injection that " mongolian medicine pharmacology " extracts from Fructus Gardeniae is to (107.48g/kg) stomach of rats, liver function has transient infringement: every day 7.5-12 gram mongolian medicine of the present invention compositions containing Fructus Gardeniae amount be about the 1/4280 of above liver damage amount, be not result in liver function injury.
" Chinese Pharmacopoeia ": do not clearly state the toxic and side effects of Fructus Gardeniae.
" Chinese medicine voluminous dictionary " (1984 editions): do not write toxic and side effects, oral dosage 24 money/time, be far longer than every day 7.5-12 gram mongolian medicine compositions of the present invention containing Fructus Gardeniae amount.
Detailed description of the invention
Embodiment 1
Choosing Radix Inulae: 1 part, Fructus Gardeniae: 3 parts, Radix Platycodonis: 10 parts, Rhizoma Coptidis: 5 parts, Lignum Sappan: 5 parts, grind to form segmentation, make powder after mix homogeneously, in units of 2.5g, dosage is packed.
Embodiment 2
Choosing Radix Inulae: 1.5 parts, Fructus Gardeniae: 4.5 parts, Radix Platycodonis: 12 parts, Rhizoma Coptidis: 8 parts, Lignum Sappan: 6 parts, grind to form segmentation, make powder after mix homogeneously, in units of 2.5g, dosage is packed.
Embodiment 3
Choosing Radix Inulae: 2 parts, Fructus Gardeniae: 6 parts, Radix Platycodonis: 15 parts, Rhizoma Coptidis: 10 parts, Lignum Sappan: 8 parts, grind to form segmentation, make powder after mix homogeneously, in units of 2.5g, dosage is packed.
Embodiment 4
Effect experiment data
Within 2011 09 month 2014 09 month, the diabetics in out-patient treatment carries out clinical observation on the therapeutic effect.
Diagnostic criteria
Mongolian medicine's diagnostic criteria
" sick kind nationality of 7 nationalitys 41 that Department of Medical Administration of State Administration of Traditional Chinese Medicine publishes doctor's diagnosis and treatment scheme is uncommon and day wishes clean (type 2 diabetes mellitus) " diagnostic criteria is foundation.
Primary symptom: polydipsia, polyuria, polyphagia, become thin, weak.
Secondary disease: xerostomia, mouth sent out sweet, like cool, dizzy, weakness of the lower extremities, cardiopalmus, insomnia, skin pruritus, infection, blurred vision.
Pulse condition: deep and slow, count accurately.
Urine: pale yellow, muddiness, amount are indefinite
Tongue: tongue fur slightly thick (yellow, white)
Mongolian medicine's syndrome diagnostic criterion
Ba Dagan contains patients with type Ⅰ DM: figure is fat, be partial to Ba Da stem body matter, tired, waist is empty, lower limb is soft, weak, dyspepsia, deep pulse, thick fur are white, urine is white, it is on the high side to measure.
He Yixilasheng patients with type Ⅰ DM: cardiopalmus, insomnia, skin irritation, thirsty polydipsia, sleep poor, pachylosis, thready and rapid pulse, yellow fur, urine yellow skin, measure on the high side.
Fine jade Su Xilasheng patients with type Ⅰ DM: giddy, conjunctival congestion, xerostomia, hungry polyphagia, become thin, constipation, cardiopalmus, fetid sweat, thready and rapid pulse, yellow fur is thick, yellow urine is smelly.
Western medicine diagnose standard
Prediabetes diagnostic criteria
Impaired fasting glucose (IFG) (IFG) and impaired glucose tolerance (IGT) are generically and collectively referred to as pre-diabetic.
Impaired fasting glucose (IFG) (IFG) diagnostic criteria:
" internal medicine " the 7th edition is foundation:
Fasting glucose 6.1 6.9mmol/L
Post-prandial glycemia 7.8mmol/L
Impaired glucose tolerance (IGT) diagnostic criteria:
" internal medicine " the 7th edition is foundation:
Fasting glucose 7.0mmol/L
Post-prandial glycemia 7.8 11.0mmol/L
Diabetes diagnostic criterion
It is foundation with reference to " diabetes mellitus in China guideline of prevention and treatment " (2011), " internal medicine " the 7th edition:
Fasting glucose >=7.0mmol/L
Or 2 hours blood glucoses >=11.1mmol/L after the meal
Or diabetic symptom+any time blood glucose >=11.1mmol/L
Or glycolated hemoglobin >=6.5%
Case inclusion criteria
Meet type 2 diabetes mellitus diagnostic criteria
Light-duty case (blood glucose≤10mmol/l)
Can oral mongolian medicine person
Can coordinate and follow up a case by regular visits to, agree to partner.
Obtain patient consenter.
Case exclusion standard
Heavy case, namely blood sugar level higher >=10mmol/l or be associated with other complication such as the serious heart, brain, kidney.
Get rid of type 1 diabetes and other types diabetes.
Allergic constitution person, namely to medicine allergy sufferers
Uncooperative, mismatch and follow up a case by regular visits to the person of examining
Case is originated
2011.09 the patient meeting type 2 diabetes mellitus diagnostic criteria that Alashan League Mongolian medicine's hospital outpatient is medical with in-patient department between 2014.09.
Case ordinary circumstance:
Male 56 examples in 100 example patients, female 44 example；Minimal ages is 40 years old, and max age is 74 years old.It is randomly divided into two groups according to medical sequencing:
Treatment group: 50 examples, male 28 examples, female 22 example, minimal ages 39 years old, max age 74 years old, average (45.3 ± 1.8) year.
Matched group: 50 examples, male 27 examples, female 23 example, minimal ages 39 years old, max age 67 years old, average (43.5 ± 4.2) year.Two groups of patients sex, the age, in comparing difference not statistically significant, there is comparability (P > 0.05).
Treatment group
Therapeutic Principle
Clear fine jade Su Xilare, balances three, according to state of an illness symptomatic treatment.
Therapeutic Method:
3g of mongolian medicine compositions of the present invention, in three times on the one morning, noon, suppers, boiled water is taken after mixing it with water.
Matched group
Therapeutic Principle:
Keep on a diet, exercise therapy.
Therapeutic Method:
Tighter control, motion, lose weight.
Efficacy assessment standard
Effective: fasting glucose is remarkably decreased earlier above, transference cure.
Effective: symptom takes a turn for the better, and fasting glucose declines earlier above.
Invalid: the symptom for the treatment of front and back and fasting glucose are without obvious change.
Total effective rate=(effective+effectively)/total number of persons.
Statistical procedures
Adopting SPSS13.0 software kit that data carry out statistical analysis, all measurement datas represent with mean ± standard deviation (x ± s), and group is asked and compared employing t inspection and variance analysis, and P < 0.05 is that difference is statistically significant.
Result
Two groups of effective 15 examples of comparitive study treatment group, effective 30 examples, invalid 5 examples；Effective 4 examples of matched group, effective 27 examples, invalid 19 examples.Two groups of total effective rates respectively 90.0% and 62.0%, difference statistically significant (P < 0.05).In Table 1
1 liang of table group comparitive study n, n (%)
Two groups of clinical symptoms, signs disappear and the blood glucose comparison therapy fall time group resolution of symptoms time；Polydipsia, polyphagia, polyuria (5.6 ± 0.70) d, blood glucose decline (5.30 ± 0.99) d；The matched group resolution of symptoms time: polydipsia, polyphagia, polyuria (11.6 ± 0.54) d, blood glucose decline (10.22 ± 0.81) d；Treatment group, matched group healing time respectively (30.02 ± 0.99) d, (45.08 ± 0.98) d；Two groups are compared, difference all statistically significant (P < 0.05).In Table 2.
2 liang of table group symptom, sign improve the time compare (x ± s, d)
Special case
Example 1.
The white XX of patient, man, 42 years old, worker, 2014.02.10 head examined.
Nearly 2 years of patient is weak substantially, and hyperhidrosis, urine is some more sometimes, it has been found that blood glucose is high 3 years, but never treats.Result of laboratory test previously is as follows:
2012.06.25 at the fasting glucose 9.8mmol/L that my Out-patient Department checks.
2013.03.27 the fasting glucose 8.69mmol/L at Ningxia army unit examination in hospital.
The fasting glucose 9.9mmol/L that (2014.02.10 examining the date at I section head) checks in my section.
Diagnosis: type 2 diabetes mellitus
Treatment: mongolian medicine compositions of the present invention 3 grams/times .3 times/day. warm boiled water in morning, noon and afternoon meal.
2014.05.26 second time is medical, patient is weak, and hyperhidrosis is all quite a lot of, checks fasting glucose 7.6mmol/L, and treatment is ibid.
2014.07.25 third time is medical, without sense of discomfort with patient, checking fasting glucose 7.1mmol/L, treatment is ibid.
Example 2.
Patient king XX, female, 57 years old, Han nationality, resident.
2014..4.18 head examines.
Nearly 1 month of patient is weak, feel sick, about the 3Kg that becomes thin, urine are many.Go to a doctor to central hospital, 2014.04.14 fasting glucose 18.53mmol/L, after the meal 2 hours blood glucose 17.87mmol/L, glycolated hemoglobin 12.5%, insulin checks 5.4mmol/L, C peptide 1.26ng/mL, carrys out my section's outpatient clinic in order to Effect of Mongolian Medicine Treating 2014.04.18 is administered orally.Indicate: patient diet is based on sweet food.
Diagnosis: type 2 diabetes mellitus
Treatment: 1. diabetes regular diet
2. mongolian medicine compositions of the present invention 3 grams/times .4 times/day. warm boiled water in morning, noon and afternoon meal, sleep front 3 grams of warm boiled waters evening.
2014.06.10 second time is medical, patient's above-mentioned symptom disappears, and checks that fasting glucose 6.7mmol/L. treats ibid.
2014.11.14 world diabetes daily inspection fasting glucose 7.3mmol/L, continue mongolian medicine mongolian medicine compositions of the present invention 3 grams/times. warm boiled water in morning, noon and afternoon meal.
Example 3.
Patient crow XX, man, 58 years old, the court worker.
2014.09. find T-CHOL 7.22mmol/L, low density lipoprotein, LDL 5.82mmol/L, uric acid 467 μm of mol/L, glutamate pyruvate transaminase 97.8 μ/L when my institute is to worker's health check-up.
2014.10.11 with hyperlipemia, liver function injury is at my institute's department of endocrinology hospitalization, hospitalized to have a thorough examination: T-CHOL 7.4mmol/L, low density lipoprotein, LDL 5.81mmol/L, 483 μm of mol/L of uric acid, glutamate pyruvate transaminase 169.6 μ/L, glutamic oxaloacetic transaminase, GOT 63 μ/L, transglutaminase 233 μ/L.
Diagnosis: 1. hyperlipemia
2. liver function injury
Treatment: because liver function injury cannot use lipid-lowering statins, therefore by mongolian medicine compositions of the present invention 3 grams/times. warm boiled water in morning, noon and afternoon meal.
2014.10.27 result of laboratory test is as follows: T-CHOL 4.73mmol/L, low density lipoprotein, LDL 3.12mmol/L, uric acid 388 μm of mol/L, glutamate pyruvate transaminase 80.1 μ/L, transglutaminase 117 μ/L.
Hyperlipemia is cured and is left hospital.
Example 4.
Patient Korea Spro XX, man, 50 years old, 2015.10.22 head examined.
Patient loses weight about 6Kg nearly half a year, thirsty, polydipsia, polyuria, polyphagia, in the medical biochemical investigation result of central hospital: fasting glucose 11.27mmol/L, low density lipoprotein, LDL 4.36mmol/L, carrys out my section's outpatient clinic in order to Effect of Mongolian Medicine Treating is administered orally.
2015.10.22 check fasting glucose 10.5mmol/L, post-prandial glycemia 17.7mmol/L, routine urinalysis detection Fructus Vitis viniferae+2 in my institute.
Diagnosis: 1.2 patients with type Ⅰ DM
2. hyperlipemia
Treatment: mongolian medicine compositions of the present invention 3 grams/times .4 times/day. warm boiled water in morning, noon and afternoon meal, sleep front 3 grams of warm boiled waters evening.
2015.11.10 second time is medical, patient is transference cure more than three, checks fasting glucose 9.4mmol/L, after the meal 2 hours blood glucose 13.7mmol/L, low density lipoprotein, LDL 2.96mmol/L, and treatment is ibid.
2014.11.24 third time is medical, checking fasting glucose 8.5mmol/L, after the meal 2 hours blood glucose 12.2mmol/L, treatment is ibid.
Example 5.
Patient Lee XX, female, 83 years old, patient's identification number 12558.
Entire patient's pruritus, more than 1 year, increases the weight of 1 week in 2016..1.06 hospitalization.Glycolated hemoglobin 6.7%, fasting glucose 7.3mmol/L, T-CHOL 7.12mmol/L, low density lipoprotein, LDL 5.07mmol/L, routine urinalysis detection glucose+3 is checked after being in hospital.
Hemorheology detects:
Diagnosis:
1. senile skin pruritus
2.2 patients with type Ⅰ DM
3. hyperlipemia
4. high blood viscosity
Treatment: treat hyperglycemia, hyperlipemia, high blood viscosity mongolian medicine compositions of the present invention 3 grams/times outside Western medicine antianaphylactic treatment. warm boiled water in morning, noon and afternoon meal, sleep front 3 grams of warm boiled waters evening.
2016.02.29 come my institute to check that result is as follows: fasting glucose 6.4mmol/L, T-CHOL 5.82mmol/L, low density lipoprotein, LDL 3.67mmol/L.
Hemorheology detects:
Result: after oral 1 first quarter moon of mongolian medicine compositions of the present invention, whole blood pol, blood reduced viscosity are remarkably decreased.
Example 6.
White XX, man, 68 years old, retirement, on June 23rd, 2015, head examined.
Nearly two months total urination time of patient are many, measure also many, thirsty, lose weight about 3 kilograms, weak come my institute's department of endocrinology outpatient clinic.
Having a medical check-up: skin elasticity is slightly worse, without other positive signs, in inspection project, liver function, renal function are all normal.
Four items of blood lipid tests:
| Detected value | Reference value | |
| T-CHOL | 6.02mmol/L | 2.85-5.7mmol/L |
| Triglyceride | 3.41mmol/L | 0.45-1.7mmol/L |
| High density lipoprotein | 1.28mmol/L | 0.78-2mmol/L |
| Low density lipoprotein, LDL | 4.36mmol/L | 0-3.7mmol/L |
Hemorheology detects:
Blood sugar test value:
| Detected value | Reference value | |
| Fasting glucose | 13.6mmol/L | 3.1-6.19mmol/L |
| Random blood sugar | 18.2mmol/L | ≥11.1mmol/L |
Diagnosis:
1. diabetes
2. hyperlipemia
3. high blood viscosity
Treatment: mongolian medicine compositions of the present invention 3.0g/ time .4 times/day.
Method: early, middle and late half an hour ante cibum and late 21:00 point warm boiled water.
Within on 09 03rd, 2015, second time is medical: patient is thirsty inconspicuous, and urine is normal, it does not have discomfort.
Four items of blood lipid tests:
| Detected value | Reference value | |
| T-CHOL | 5.72mmol/L | 2.85-5.7mmol/L |
| Triglyceride | 1.85mmol/L | 0.45-1.7mmol/L |
| High density lipoprotein | 1.29mmol/L | 0.78-2mmol/L |
| Low density lipoprotein, LDL | 3.67mmol/L | 0-3.7mmol/L |
Blood sugar test value:
| Detected value | Reference value | |
| Fasting glucose | 9.8mmol/L | 3.1-6.19mmol/L |
| Random blood sugar | 13.6mmol/L | ≥11.1mmol/L |
Hemorheology detects:
Summing up: above illustrate that mongolian medicine compositions of the present invention is notable to hyperglycemia, hyperlipidemia, high blood viscosity patient outcome, the multinomial high level item in treatment blood fat, the Hemorheology of 70 days drops to normal value or close to normal value.The amplitude that fasting glucose, random blood sugar value drop is bigger.
Illustrate: above treatment there is not band western medicine.
Claims (2)
1. the mongolian medicine compositions of eutherapeutic treatment diabetes, hyperlipemia, constitutional high blood viscosity, it is characterized in that described mongolian medicine compositions is made up of following weight proportion raw material: Radix Inulae: 1-2 part, Fructus Gardeniae: 3-6 part, Radix Platycodonis: 10-15 part, Rhizoma Coptidis: 5-10 part, Lignum Sappan: 5-8 part.
2. mongolian medicine compositions according to claim 1, wherein preferably composition proportion is: Radix Inulae: 1.5 parts, Fructus Gardeniae: 4.5 parts, Radix Platycodonis: 12 parts, Rhizoma Coptidis: 8 parts, Lignum Sappan: 6 parts.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610154734.4A CN105770087B (en) | 2016-03-17 | 2016-03-17 | Mongolian medicinal composition for treating diabetes, hyperlipidemia and primary hyperviscosity |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610154734.4A CN105770087B (en) | 2016-03-17 | 2016-03-17 | Mongolian medicinal composition for treating diabetes, hyperlipidemia and primary hyperviscosity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105770087A true CN105770087A (en) | 2016-07-20 |
| CN105770087B CN105770087B (en) | 2020-12-29 |
Family
ID=56392843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610154734.4A Active CN105770087B (en) | 2016-03-17 | 2016-03-17 | Mongolian medicinal composition for treating diabetes, hyperlipidemia and primary hyperviscosity |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105770087B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113559215A (en) * | 2021-08-10 | 2021-10-29 | 锡林郭勒盟蒙医医院(锡林郭勒盟蒙医研究所、锡林浩特市人民医院) | Medicine for improving human body excretion and its preparation method |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101085079A (en) * | 2007-07-06 | 2007-12-12 | 陈奇 | Traditional Chinese medicine compound for treating diabetes and its preparation method and application |
-
2016
- 2016-03-17 CN CN201610154734.4A patent/CN105770087B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101085079A (en) * | 2007-07-06 | 2007-12-12 | 陈奇 | Traditional Chinese medicine compound for treating diabetes and its preparation method and application |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113559215A (en) * | 2021-08-10 | 2021-10-29 | 锡林郭勒盟蒙医医院(锡林郭勒盟蒙医研究所、锡林浩特市人民医院) | Medicine for improving human body excretion and its preparation method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105770087B (en) | 2020-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mourão et al. | Homeopathy and periodontal treatment in type II diabetic patients: a 1-year randomized clinical trial | |
| Dehghanmehr et al. | Effect of oral saffron capsules on sleep quality in patients with diabetes at Zabol-Iran | |
| CN103417950B (en) | A kind of Chinese medicine composition merging dyslipidemia for preventing and treating obese type 2 diabetes mellitus | |
| CN110327437B (en) | Traditional Chinese medicine for treating chronic diarrhea and preparation method thereof | |
| CN105770087A (en) | Mongolian medicine composition for treating diabetes mellitus, hyperlipidemia and primary hyperviscosity | |
| Fadheel | A comparative study of the effect of metformin and metformin plus garlic on blood glucose level in patients with type 2 diabetes mellitus in Iraq | |
| CN107837384A (en) | A kind of Chinese medicine composition for treating hand-foot-and-mouth disease | |
| Misael et al. | Effect of Cynara scolymus (artichoke) in homeopathic doses on body mass index in obese and overweight patients | |
| Devonish et al. | Novel considerations about diabetes management strategies in chinese immigrants in america: Possible corollaries of the use of traditional chinese medicines | |
| CN105456734A (en) | Traditional Chinese medicine for treating diabetes | |
| Zamani et al. | The effect of oral supplementation of cinnamon on weight loss and blood pressure in patients with type 2 diabetes: A randomized clinical trial | |
| KR20210096121A (en) | Antidiabetic activity of neem extract and synergistic combination of urolitin A and B | |
| CN104257960A (en) | Traditional Chinese medicine composition for treating non-alcoholic fatty liver disease and applications of composition | |
| CN117018105B (en) | Traditional Chinese medicine composition for treating impaired glucose tolerance and preparation method thereof | |
| Kassis | A Randomized, Double-Blind, Placebo-Controlled Study of a Blend of Herbal Extracts Taken Once Per Day for Weight Loss in Healthy Volunteers | |
| AU2021100530A4 (en) | Mongolian medicine composition for treating diabetes, hyperlipidaemia and primary hyperviscosity | |
| CN116059302B (en) | Traditional Chinese medicine composition for treating gastrointestinal motility diseases and preparation method and application thereof | |
| CN114191513B (en) | Traditional Chinese medicine composition for treating damp-heat type obesity | |
| Rani et al. | A study comparing the effect of Glimepiride and Glibenclamide on Glycosylated Hemoglobin (HbA1c) in Type II Diabetes Mellitus patients | |
| Dalvi et al. | Evaluation of biochemical markers in type 2 diabetes mellitus with adjunct therapy of fenugreek seed aqueous extract | |
| Guanjie et al. | Fan's Eight Methods of Action-determination Sequence of Chinese Medicine for Alleviating Type 2 Diabetes Mellitus Combined with Various Metabolic Disorders | |
| Chowdhury et al. | Study Of Medicinal Plant-Based Anti-Stress Herbal Tea On Prediabetic Women: Randomized Controlled Trial | |
| Ota et al. | Clinical Safety of Selected Ayurvedic Formulations in Diabetes Mellitus–A Pharmaco-epidemiological Perspective | |
| CN105395829A (en) | Efficient blood sugar lowering drug | |
| Eom et al. | A 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial Evaluating the Efficacy and Safety of DKB-131 in Knee Arthritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20171214 Address after: 750306 the Inner Mongolia Autonomous Region Alashanzuoqi of Alashan Bayehot elute Road No. 21 Applicant after: Alashan Mongolian hospital (Alashan Mongolian Medicine Research Institute) Address before: 750306 the Inner Mongolia Autonomous Region Alashan Mongolian hospital Applicant before: Ma Xiulan |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |